Physician profile
Graeme Marquez
NPI 1245801588
$503.45
in general payments reported to CMS, 2019-2025
19 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.99 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $491.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $64.15 | 2025 | Gardasil 9, Capvaxive, M-M-R II |
| Exact Sciences Corporation | $45.57 | 2025 | The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $38.90 | 2025 | Rexulti |
| Pfizer INC. | $36.37 | 2025 | |
| Novo Nordisk INC | $34.40 | 2025 | Wegovy |
| Glaxosmithkline, LLC. | $33.31 | 2025 | Trelegy Ellipta |
| Edwards Lifesciences Corporation | $28.79 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Aimmune Therapeutics, INC. | $23.29 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $22.82 | 2025 | Rezdiffra |
| Abbvie INC. | $21.28 | 2025 | |
| Novartis Pharmaceuticals Corporation | $20.69 | 2025 | |
| Ascendis Pharma Endocrinology INC | $20.59 | 2025 | Yorvipath |
| Amgen INC. | $18.70 | 2025 | Evenity |
| Bioventus LLC | $17.30 | 2025 | Durolane |
| Verity Pharmaceuticals INC. | $16.77 | 2025 | Tlando |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $16.46 | 2025 | Keveyis |
| Lilly USA, LLC | $16.24 | 2025 | Jardiance |
| Corcept Therapeutics | $15.83 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Graeme Marquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.